

LIST OF TABLES

Table no.	Title	Page no.
2.1.1	Number of DALYs for neurological disorders and as percentage of global DALYs projection	15
2.1.2	DALYs per 100,000 population for neurological disorders globally and by World bank income category	15
2.1.3	Deaths attributable to neurological disorders as percentage of total deaths by World Bank income category	18
2.2.1	Number of people with dementia (millions) according to 2015 World Bank classification	21
2.2.2	Common subtypes of irreversible dementia	27
2.3.1	Criteria for MCI and CIND	33
2.3.2	Criteria developed to characterize cognitive impairments in non- demented elderly subjects	33
2.3.3	MCI subtypes by etiology, pathology, presentation and outcomes	35
2.3.4	Contributing factors for MCI	38
2.4.1	Putative clinical and biological markers of the distinct stages in the AD continuum, and respective therapeutic interventions	46
2.7.1	Clinical Manifestations of Vitamin B12 Deficiency	64
2.7.2	Etiologies of Vitamin B12 Deficiency	68
2.7.3	Schedule for Vitamin B12 therapy	71
2.8.1	Recommended intake of essential PUFA	80
2.8.2	Alpha-linolenic acid content of various foods	81
2.8.3	Fish and sea food sources of DHA plus EPA	81
3.1.1	Lower limit of normal (cut-off scores) for total ACE-R and sub-scores according to age (50-59, 60-69, 70-75, 80-85), showing control mean minus two standard deviations	100
3.1.2	Cut-offs representing Mini-Mental State Examination (MMSE) scores	100
3.1.3	Cut-offs for Physical Activity Levels	103
3.1.4	Cut-offs for Body Mass Index (BMI)	105

Table no.	Title	Page no.
3.1.6	Cut-offs for Waist Hip Ratio (WHR)	106
3.1.7	Classification of Blood Pressure for Adults	107
3.1.8	Cut offs for HbA _{1c}	109
3.1.9	Cut offs for Serum Cholesterol	110
3.1.10	Cut offs for Triglycerides	111
3.1.11	Cut offs for HDL Cholesterol	112
3.1.12	Cut offs for LDL Cholesterol	113
3.2.2.1	Inclusive list of raw ingredients with their procurement sources used for product development	118
4.1.1.1	Neurological status of baseline population detected by ACE screening test	133
4.1.1.2	Neurological status of baseline population detected by MMSE screening test	133
4.1.1.3	Neurological status of baseline population detected by YFPIT screening test	134
4.1.1.4	Neurological status of baseline population detected by MNA screening test	134
4.1.1.5	Impact of age on nutritional status	135
4.1.2.1	Socio-demographic characteristics of the baseline subjects	136
4.1.3.1	Socio economic characteristics of MCI patients	140
4.1.5.1	Distribution of MCI subjects according to their weekly physical activity pattern	142
4.1.5.2	Daily Activity Pattern of MCI Subjects (in minutes)	143
4.1.6.1	Mean values of anthropometric measurements of the MCI subjects	143
4.1.6.2	BMI Classification of MCI subjects according to Asia-Pacific classification	144
4.1.7.1	Mean Values for Biophysical and Biochemical profile of MCI Subjects	145
4.1.7.2	Biophysical status of the MCI subjects	146
4.1.7.3	Glycemic and lipemic status of the MCI subjects categorized	146

Table no.	Title	Page no.
4.1.7.4	Anthropometric, Biophysical and Biochemical profiles of the MCI subjects based on age groups	148
4.1.7.5	Mean values for biophysical and biochemical profile of MCI subjects based on their glycated hemoglobin status	149
4.1.7.6	Mean values for biophysical and biochemical profile of MCI subjects based on their total cholesterol levels	150
4.1.8.1	Food habits of the MCI Subjects	151
4.1.8.2	Mean intake of nutrients of MCI subjects as per 24 hour dietary recall	152
4.1.9.1	Frequency of consumption of food groups by the subjects as per food frequency method	154
4.1.9.2	Frequency of consumption of Vitamin B12 and Omega 3 rich food sources by the patients as per food frequency questionnaire	155
4.1.10.1	Correlation between neurological test scores and other parameters in MCI patients	156
4.1.11.1	Correlation between omega 3 intake and B12 serum levels with other parameters in MCI patients	157
4.2.1.1	Proximate analysis of raw versus roasted flaxseeds	167
4.2.2.1	Effect of substitution of roasted flaxseeds at various levels with base material in <i>khichdi</i> using mean hedonic scores of panelists	172
4.2.2.2	Effect of variations of roasted flaxseeds on organoleptic qualities of <i>khichdi</i> using Composite scores	174
4.2.2.2.1	Effect of substitution of roasted flaxseeds at various levels with base material in <i>porridge</i> using mean hedonic scores of panelists	176
4.2.2.2.2	Effect of variations of roasted flaxseeds on organoleptic qualities of <i>porridge</i> using Composite scores	178
4.2.2.3.1	Effect of substitution of roasted flaxseeds at various levels with base material in <i>globs (laddoo)</i> using mean hedonic scores of panelists	180

Table no.	Title	Page no.
4.2.2.3.2	Effect of variations of roasted flaxseeds on organoleptic qualities of <i>globs</i> using mean composite scores	182
4.2.2.4.1	Effect of 20g roasted flaxseeds mukhwaas using mean hedonic scores of panelists	185
4.2.2.4.2.	Effect on organoleptic qualities of 20g roasted flaxseeds mukhwaas using mean Composite scores	185
4.3.1.1	Odds of hypertension between baseline and MCI subjects	194
4.3.1.2	Odds of abnormal BMI values between baseline and MCI subjects	194
4.3.1.3	Anthropometric and Biophysical profile of MCI subjects before and after supplementation	195
4.3.1.4	Anthropometric and Biophysical profile of MCI subjects before and after supplementation in Group1 (B12)	196
4.3.1.5	Anthropometric and Biophysical profile of MCI subjects before and after supplementation in Group2 (Flaxseeds plus B12)	197
4.3.1.6	Biophysical profile according to stages of hypertension in Group 1 (B12) and Group 2 (Flaxseeds plus B12) MCI patients	198
4.3.2.1	Nutrient intake of MCI patients before and after supplementation	199
4.3.3.1	Glycemic response of MCI subjects before and after supplementation	200
4.3.3.2	Glycemic profile of MCI subjects before and after supplementation in Group 1 (B12)	201
4.3.3.3	Glycemic profile of MCI subjects before and after supplementation in Group 2 (flaxseeds plus B12)	202
4.3.4.1	Lipemic response of MCI subjects before and after supplementation	202
4.3.4.2	Lipemic response of MCI subjects before and after supplementation in Group 1 (B12)	204
4.3.4.3	Lipemic response of MCI subjects before and after supplementation in Group 2 (Flaxseeds plus B12)	205

Table no.	Title	Page no.
4.3.5.1	Atherogenic indices of MCI patients before and after supplementation	206
4.3.5.2	Atherogenic indices of MCI subjects before and after supplementation in Group 1 (B12)	208
4.3.5.3	Atherogenic indices of MCI subjects before and after supplementation in Group 2 (Flaxseeds + B12)	209
4.3.6.1	Serum vitamin B12 and CBC profile of MCI subjects before and after supplementation	210
4.3.6.2	Serum Vitamin B12 and CBC profile of MCI subjects before and after supplementation in Group 1 (B12)	211
4.3.6.3	Serum Vitamin B12 and CBC profile of MCI subjects before and after supplementation in Group 2 (Flaxseeds plus B12)	212
4.3.7.1	Pre and post MMSE score of MCI patients in supplementation Group 1 (vitamin B12)	213
4.3.7.2	Pre and post ACE score of MCI patients in the supplementation Group 1	213
4.3.7.3	Pre and post MNA score of MCI patients in Group 1	214
4.3.7.4	Pre and post MMSE score of MCI patients in supplementation Group 2 (flaxseeds plus Vitamin B12)	214
4.3.7.5	Pre and post ACE score of MCI patients in the supplementation Group 2	215
4.3.7.6	Pre and post MNA score of MCI patients in supplementation Group 2	216
4.3.7.7	Improvement in MCI patients to normal cognition levels aided through MMSE detection	216
4.3.7.8	Improvement in MCI patients to normal cognition levels aided through ACE detection	217
4.3.7.9	Improvement in MCI patients to normal cognition levels aided through YFPIT detection	218
4.3.7.10	Improvement in Group 1 MCI patients to normal nutrition levels aided through MNA detection	219

Table no.	Title	Page no.
4.3.7.11	Improvement in Group 2 MCI patients to normal nutrition levels aided through MNA detection	220
4.3.8.1	Correlation amongst change in glycemic factors with change in serum vitamin B12 and dietary Omega-3 levels	221
4.3.9.1	Correlation amongst change in anthropometric and biophysical factors with change in serum Vitamin B12 and Omega-3 levels	222
4.3.9.2	Correlation amongst change in neurological and nutritional assessment scores with change in B12 and omega-3 intake levels	222

LIST OF FIGURES

Figure no.	Title	Page no.
2.1.1	DALYs for individual neurological disorders as percentage of total neurological disorders	16
2.1.2	DALYs per 100,000 population associated with neurological disorders by WHO	16
2.1.3	Deaths from selected neurological disorders as percentage of total neurological disorders	17
2.2.1.a	Prevalence of Dementia in India, 2010	22
2.2.1.b	Trend in dementia prevalence in age over time	22
2.2.1.c	Estimation of number of people with dementia over 60 years in India between 2000 and 2050	23
2.2.1.d	Estimation of people with dementia > India, US, UK	23
2.2.2	Projected changes between 2006 and 2026 in number of people living with dementia by state	26
2.2.3	Need for care among people with dementia	29
2.3.1	Diagnostic algorithm for diagnosing and subtyping MCI	34
2.3.2	Predicted outcome of MCI subtypes according to presumed aetiology	35
2.3.3	Hypothetical model of the pathological processes in Alzheimer's disease (AD), focusing on the amyloid β peptide ($A\beta$) cascade	39
2.3.4	Relationship between the progression of cognitive and functional symptoms and the neuropathological events in the transition from asymptomatic Alzheimer's disease (AD) to mild cognitive impairment due to AD and clinically manifest dementia of the AD type.	41
2.4.1	Hypothetical outcomes according to distinct mild cognitive impairment (MCI) subtypes	43
2.5.1	The brain-gut-microbiota axis	52
2.5.2	Potential neuropsychiatric consequences of a dysregulated intestinal barrier	54

Figure no.	Title	Page no.
2.7.1	Chemical structures of vitamin B12 forms	62
2.7.2	Vitamin B12 absorption and transport	66
2.7.3	Vitamin B ₁₂ deficiency leads to a serum build-up of methylmalonic acid. Deficiency of vitamin B ₁₂ or folic acid can lead to increased homocysteine levels	67
2.7.4	Metabolic relationship between folate, Vitamin B12 and homocysteine	72
2.8.1	Structure of α -Linolenic acid (ALA)	78
2.8.2	Structures of Eicosapentaenoic acid (EPA) and Docosahexaenoic acid (DHA)	78
2.8.3	Synthesis of ω -3 polyunsaturated fatty acids (PUFAs).	79
3.1.1	Experimental Design of Phase I	96
3.1.2	Step-wise instructions for Yamaguchi Fox Pigeon Imitation Test	102
3.2.1	Experimental design of Phase II of the study	119
3.2.2.2	Analytical procedure for raw and roasted flaxseeds using GC technique	121
3.2.2.6.1.a-d	Roasted flaxseeds incorporated <i>khichdi</i> , <i>porridge</i> , <i>globs</i> and <i>mukhwaas</i>	124
3.2.2.6.2	Semi-trained panelists performing organoleptic evaluation of formulated flaxseed recipes	124
4.1.1	ROC curves of two diagnostic parameters (ACE test scores versus serum vitamin B12).	131
4.1.2	ROC curves of two diagnostic parameters (MMSE test scores versus serum vitamin B12).	131
4.1.3	ROC curves of two diagnostic parameters (YFPIT test scores versus serum vitamin B12)	132
4.1.2.1	BMI distribution of baseline subjects (N=402)	138
4.1.2.2	Bio-physical distribution of baseline subjects (N=402)	138
4.1.4.1	Associated health problems prevalent in MCI Subjects	141
4.1.5.1	Physical activity pattern of MCI subjects	142

Figure no.	Title	Page no.
4.1.6.1	Classification of MCI subjects according to BMI according to Asia Pacific Classification	144
4.1.7.1.a	Percent distribution of patients with varying hypertensive levels	147
4.1.7.1.b	Percentage of patients with varying control of glycate hemoglobin	147
4.1.7.1.c	Percentage of MCI patients with varying control of serum vitamin B12 levels	147
4.1.8.1	Ideal % distribution of energy vs % distribution of energy by the subjects	153
4.2.1.1	Chromatograph depicting fatty acid profile of raw flaxseeds	168
4.2.1.2	Chromatograph depicting fatty acid profile of roasted flaxseeds	169
4.2.2.1	Mean hedonic scores of flaxseed variations in <i>khichdi</i> by semi-trained and untrained panelists	173
4.2.2.2	Mean composite scores of flaxseed variations in <i>khichdi</i> by semi-trained panelists	175
4.2.2.2.1	Mean hedonic scores of flaxseed variations in <i>porridge</i> by semi-trained and untrained panelists	177
4.2.2.2.2	Mean composite scores of flaxseed variations in <i>porridge</i> by semi-trained panelists	179
4.2.2.3.1	Mean hedonic scores of flaxseed variations in <i>globs</i> by semi-trained and untrained panelists	181
4.2.2.3.2	Mean composite scores of flaxseed variations in <i>globs</i> by semi-trained panelists	183
4.2.2.4.1	Mean composite scores of 20g flaxseed <i>mukhwaas</i> (M1) by semi-trained and untrained panelists	186
4.2.2.5	Score card of mean composite scores of overall formulated flaxseed variations assessed by semi-trained panelists	187
4.3.1.1	Biophysical trend in Group 1 (B12) MCI patients before and after supplementation	198

Figure no.	Title	Page no.
4.3.1.2	Biophysical trend in Group 2 (Flaxseeds plus B12) MCI patients before and after supplementation	198
4.3.3.1.a	Glycemic response of MCI patients before and after supplementation	200
4.3.3.1.b	Glycemic response of MCI patients before and after supplementation	201
4.3.4.1	Lipemic response of MCI subjects before and after supplementation	203
4.3.5.1	Atherogenic Coefficient of the of MCI subjects before and after supplementation	207
4.3.7.1	MMSE Scores of MCI patients before and after in both supplementation groups	217
4.3.7.2	ACE Scores of MCI patients before and after in both supplementation groups	218
4.3.7.3	YFPIT Scores of MCI patients before and after in both the supplementation groups	219
4.3.7.4	MNA Scores of MCI patients before and after in the Group 1 of supplementation	220
4.3.7.5	MNA Scores of MCI patients before and after in the Group 2 of supplementation	221